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Iron chelation therapy is essential in patients with b-thal-
assaemia major undergoing regular transfusion therapy
to potentially prevent the serious clinical sequelae of
transfusional iron overload, such as cardiac failure. Eval-
uation of the long-term effect of iron chelation in paedi-
atric patients with thalassaemia is of particular
importance because of the known negative impact on
growth and development of iron toxicity to endocrine
organs (1–3) and adverse effects of deferoxamine (DFO,
Desferal
 ) treatment (4, 5).
Previous studies with the once-daily oral iron chelator
deferasirox (Exjade
 ) have demonstrated that dosing
should be guided by the patient’s current iron burden
and ongoing transfusional iron intake (6–8). The ESCA-
LATOR (Efﬁcacy and Safety of long-term treatment
with ICL670 in b-thALAssaemia patients with Transfu-
sional hemOsideRosis) study was designed to evaluate
the efﬁcacy of deferasirox initiated at a dose of
20 mg⁄kg⁄d, followed by dose adjustments in response
to efﬁcacy and safety markers. The study enrolled heav-
ily iron-overloaded patients with b-thalassaemia major,
all of whom were previously unsuccessfully chelated with
DFO and⁄or deferiprone (Ferriprox
 ) (9). Following
1-yr treatment with deferasirox, 57% of patients achieved
Abstract
Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with
b-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC)
vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26 wk, suggesting that 1-yr
results may not have reﬂected full deferasirox efﬁcacy. Extension data are presented here. Deferasirox
starting dose was 20 mg⁄kg⁄d (increases to 30⁄40 mg⁄kg⁄d permitted in the core⁄extension, respec-
tively). Efﬁcacy was primarily assessed by absolute change in LIC and serum ferritin. Overall, 231 patients
received deferasirox in the extension; 67.4% (P < 0.0001) achieved treatment success. By the end of the
extension, 66.2% of patients were receiving doses ‡30 mg⁄kg⁄d. By the end of the 1-yr extension, mean
LIC had decreased by 6.6 ± 9.4 mg Fe⁄g dw (baseline 19.6 ± 9.2; P < 0.001) and median serum ferritin by
929 ng⁄mL (baseline 3356; P < 0.0001). There was a concomitant improvement in liver function markers
(P < 0.0001). Fewer drug-related adverse events were reported in extension than core study (23.8% vs.
44.3%). Doses ‡30 mg⁄kg⁄d were generally required because of high transfusional iron intake and high
baseline serum ferritin levels, highlighting the importance of administering an adequate dose to achieve
net negative iron balance.
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ª 2011 John Wiley & Sons A/S 355treatment success (maintenance of or reduction in LIC
depending on baseline LIC). To achieve these therapeutic
goals, 78% of patients required dose increases above the
20 mg⁄kg⁄d starting dose; however, most of these
patients did not receive a dose increase to ‡25 mg⁄kg⁄d
until more than halfway through the 1-yr study (9).
Therefore, the effect of deferasirox on LIC and serum
ferritin levels after 1 yr of treatment may not have fully
reﬂected the efﬁcacy of this dosing strategy because
patients received insufﬁcient chelation to achieve net iron
reduction while being transfused on an ongoing basis. In
this study, we report the efﬁcacy and safety of deferasi-
rox during the ESCALATOR extension study, which col-
lected data for at least 1 additional year of treatment.
Methods
Study design and patient recruitment
The ESCALATOR study was a prospective, open-label
multicentre trial conducted at seven sites in the Middle
East; data reported in this study are acquired from
patients from six sites (9). The seventh site was excluded
for a good clinical practice (GCP) reason. Patients aged
‡2 yr with b-thalassaemia and transfusional iron over-
load (LIC ‡2m gF e⁄g dry weight [dw] and serum ferritin
‡500 ng⁄mL) were recruited to the 1-yr core study; all
enrolled patients had previously been suboptimally che-
lated with DFO and⁄or deferiprone. Paediatric patients
were classiﬁed as aged 2–<16 yr and adults as aged
‡16 yr. Patients who completed the core study were eligi-
ble for inclusion in the extension study, which lasted for
an additional 2 yr or until deferasirox became commer-
cially available locally, whichever came ﬁrst. Patients
who were taken off the study for the latter reason were
considered to have completed treatment. All patients (or
parents⁄guardians) provided written, informed consent,
and the study was conducted in accordance with GCP
guidelines and the Declaration of Helsinki.
Dose selection
In the 1-yr core study, all patients started treatment with
deferasirox 20 mg⁄kg⁄d, except for three patients who
received an initial dose of 10 mg⁄kg⁄d. This dose was
subsequently increased to 20 mg⁄kg⁄d based on protocol
amendment. Dose adjustments in the range 0–
30 mg⁄kg⁄d were permitted in the core and extension
studies. Deferasirox dose at the start of the extension
study was based on the ﬁnal dose in the core study.
Throughout the core and extension studies, routine dose
adjustments in the increments of 5 or 10 mg⁄kg⁄d were
performed based on efﬁcacy (serum ferritin trends) and
safety markers. Following a protocol amendment, dose
increases above 30 mg⁄kg⁄d were permitted from the
start of the extension study (total dose range 0–40
mg⁄kg⁄d). Doses were increased if serum ferritin levels
increased by ‡1000 ng⁄mL above baseline on two con-
secutive visits or were >2500 ng⁄mL (changed to
>1000 ng⁄mL in amendment 4) without a decreasing
trend (or >500 ng⁄mL with an increasing trend, added
in amendment 4). Deferasirox administration was inter-
rupted if serum ferritin levels fell to £500 ng⁄mL on two
consecutive visits and subsequently resumed if serum
ferritin levels rose to ‡1000 ng⁄mL (changed to
>500 ng⁄mL in amendment 4). Amendment 4 of the
protocol was introduced in the extension study and
affected only a few patients. Doses were reduced if the
patient displayed elevated levels of serum creatinine,
urinary protein⁄creatinine ratio and transaminases, and
in response to adverse events (AEs).
Assessments
The primary objectives during the extension study were
to allow patients treated with deferasirox during the core
to continue on study drug and to monitor the long-term
safety and tolerability of deferasirox. The primary efﬁ-
cacy endpoint of the study was treatment success, deﬁned
as a reduction in LIC of ‡3m gF e⁄g dw if baseline LIC
was ‡10 mg Fe⁄g dw, or ﬁnal LIC of 1–<7 mg Fe⁄gd w
if core baseline LIC was 1–<7 or ‡7–<10 mg Fe⁄g dw.
This success deﬁnition reﬂects the treatment goals of
maintenance or reduction of iron burden according to the
patient’s baseline status. Secondary efﬁcacy endpoints
were absolute change from core baseline in LIC and
serum ferritin levels. LIC was determined by biopsy for
all patients at core baseline and after 1 yr of treatment at
the end of the core study; all measurements were
performed in a central laboratory using atomic absorption
spectrometry and were performed according to standar-
dised procedures. In the extension study, LIC was deter-
mined by R2 magnetic resonance imaging (MRI) for all
patients at extension baseline, after 1 yr of treatment and
at the end of the extension study. LIC was assessed by
MRI measurements of the proton transverse relaxation
parameter R2 using 5-mm axial slices. R2 scans were per-
formed using FerriScan
  technology (Resonance Health)
(10). Serum ferritin levels were assessed at baseline and
every 4 wk as a potential surrogate marker for LIC.
Safety and tolerability were also evaluated across the
study period by monitoring the incidence and type of
AEs and by assessing routine laboratory parameters. Left
ventricular ejection fraction (LVEF) was assessed using
2-dimensional echocardiography at rest and on exertion
at core baseline and at 6-month intervals throughout the
core and the extension studies. To ensure consistency,
the same cardiologist at each participating centre inter-
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means of returned tablet counts. Paediatric assessments
of growth were performed based on change in height,
which was measured using a Harpenden Stadiometer (11)
at core baseline and regularly throughout treatment and
expressed as height standard deviation scores (h-SDS).
SDS are standardised normal distributed scores with
mean 0 and standard deviation 1 of an age- and gender-
speciﬁc normal population. Pubertal stage (female breast
development and male testes volume) was scored every
3 months with a physical examination according to the
Tanner staging system (12, 13).
Statistical methods
The statistical methods used to analyse efﬁcacy in the
extension study were as previously described for the core
study (9). The intent-to-treat efﬁcacy analysis included
all patients enrolled in the extension study. Efﬁcacy data
are primarily presented for the ﬁrst 2 yr of deferasirox
treatment only, i.e. the 1-yr core study and year 1 of the
extension study. This is because the protocol mandated
that patients were to be taken off the study once defer-
asirox became commercially available in their country; as
such, patients received study drug for a very variable
duration and only a small number completed year 2 of
the extension although they continued to receive deferasi-
rox outside of the trial. In addition, because patients
were not dose escalated to ‡30 mg⁄kg⁄d until after the
core study, efﬁcacy data stratiﬁed by mean actual dose
(<30 and ‡30 mg⁄kg⁄d) were only calculated and pre-
sented during year 1 of the extension study. This was to
ensure that there were a sufﬁcient number of patients in
the higher-dose cohort from which to draw more robust
efﬁcacy conclusions.
All patients who received at least one dose of study
medication in the extension study were included in the
safety population. Safety data are presented for the
entire treatment period, i.e. including year 2 of the exten-
sion study. Safety data stratiﬁed by mean actual dose
(<30 and ‡30 mg⁄kg⁄d) were therefore calculated and
presented from baseline in the core study.
Results
Patient characteristics
Overall, 237 patients [162 paediatric patients (aged
2–<16 yr) and 75 adults (aged ‡ 16 yr)] were included in
the core study and 233 (162 paediatric patients and 71
adult patients) completed 1 yr of treatment; 231 of these
patients entered year 1 of the extension study and
received deferasirox (Table 1). There were 162 paediatric
patients and 69 adults. Two additional adult patients
entered year 1 of the extension study, but did not receive
study drug because serum ferritin levels dropped below
the protocol-speciﬁed target of 500 ng⁄mL and did not
subsequently increase to above 1000 ng⁄mL. In total,
167 patients (120 paediatric patients and 47 adult
patients) entered year 2 of the extension study.
Table 1 Demographic and baseline character-
istics of patients who received ‡1 dose of
deferasirox during the extension study
Paediatric patients
(n=162)
Adult patients
(n=69)
Mean age ± SD, yr 9.5 ± 3.6 21.2 ± 5.8
Female⁄male, n 80:82 34:35
Race (Caucasian⁄Oriental⁄other), n 59:82:21 11:38:20
History of hepatitis B only, n (%) 0 (0) 0 (0)
History of hepatitis C only, n (%) 41 (25.3) 26 (37.7)
History of hepatitis B and C, n (%) 3 (1.9) 1 (1.4)
Splenectomy, n (%) 46 (28.4) 47 (68.1)
Previous chelation therapy, n (%)
Deferoxamine (DFO) monotherapy 145 (89.5) 39 (56.5)
Deferiprone monotherapy 1 (0.6) 3 (4.3)
DFO + deferiprone
1 16 (9.9) 27 (39.1)
Median duration of previous chelation
therapy (range), yr
2
5.2 (0.1–13.2) 12.2 (3.1–21.0)
Mean transfusion history duration ± SD, yr 8.6 ± 3.7 18.9 ± 5.6
Mean number of transfusion sessions in
the year prior to study entry ± SD
15.5 ± 4.4 14.3 ± 3.8
Mean amount transfused in the year
prior to study entry ± SD, mL⁄kg⁄d
0.50 ± 0.18 0.39 ± 0.17
SD, standard deviation.
1Patients had received prior chelation with DFO and deferiprone, although these may not have
been given in combination.
2Paediatric patients n=121 and adult patients n=49.
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Overall, patients received deferasirox for a median dura-
tion of 140 wk (range 59–161; 2.7 yr). In the 1-yr core
study, overall mean actual deferasirox dose was
22.2 ± 3.5 mg⁄kg⁄d (21.6 ± 3.3 and 24.0 ± 3.4 mg⁄kg⁄d
in paediatric and adult patients, respectively). In the
extension study, over a median period of 1.7 yr, mean
actual deferasirox dose was 27.1 ± 5.6 mg⁄kg⁄d (26.8 ±
5.2 and 27.9 ± 6.6 mg⁄kg⁄d in paediatric and adult
patients, respectively). When dosing was evaluated dur-
ing year 1 of the extension study only, 59 patients
(25.5%) received average actual deferasirox doses
‡30 mg⁄kg⁄d (mean 32.2 ± 1.6); 172 (74.5%) received
actual doses of <30 mg⁄kg⁄d (mean 24.6 ± 4.4).
Overall, 206 of 231 patients (89.2%) had at least one
dose increase during the core or extension study, which
occurred after a median of 38 wk (range 3–132). Time to
ﬁrst dose increase was longer in paediatric (40 wk, range
3–132) than in adult patients (26 wk, range 4–116). The
most common dose increase was from 20 to 30 mg⁄kg⁄d
(146 patients) during the core and extension. In the exten-
sion study, 140 patients (60.6%) had at least one dose
increase; median time to increase was comparable among
paediatric (35 wk, range 3–89) and adult patients (33 wk,
range 4–81). During the extension study, six patients
(2.6%) had dose decreases and 13 patients (5.6%) had
dose interruptions because of AEs or abnormal labora-
tory values. Dose decreases or temporary interruptions
occurred in four (1.7%) and 15 (6.5%) patients, respec-
tively, who achieved their therapeutic goal. At the end of
the extension study, the ﬁnal deferasirox dose was
‡30 mg⁄kg⁄d in 153 patients [66.2%; 112 paediatric
patients (69.1%) and 41 adult patients (59.4%)]. During
the core and extension studies, 220 patients (95.2%) were
>90% compliant with deferasirox therapy.
Transfusional iron intake
Over the course of the 2.7-yr study, mean transfusional
iron intake in patients who completed the study was
0.33 ± 0.09 mg⁄kg⁄d and iron intake was signiﬁcantly
higher in paediatric (0.35 ± 0.09 mg⁄kg⁄d; n=120)
than in adult patients (0.28 ± 0.08 mg⁄kg⁄d; n=41)
(P < 0.0001). Transfusional iron intake was also differ-
ent across deferasirox dose cohorts (0.32 ± 0.09 mg⁄kg⁄d
for <30 mg⁄kg⁄d cohort and 0.40 ± 0.10 mg⁄kg⁄df o r
‡30 mg⁄kg⁄dc o h o r t[ P = 0.0008]), reﬂecting the need for
higher doses in response to higher ongoing iron intake.
Efﬁcacy
Treatment success and overall efﬁcacy. Overall treatment
success rate from core baseline to the end of year 1 of
the extension study was 67.4% (95% conﬁdence intervals
[CI] 61.4–73.4%; P < 0.0001). In the paediatric and
adult populations, treatment success rate was 63.0%
(95% CI 55.5–70.4%) and 77.5% (95% CI 67.8–87.2),
respectively. Of 69 patients with baseline serum ferritin
levels <2500 ng⁄mL, 64 (92.8%) of these patients main-
tained a serum ferritin level <2500 ng⁄mL by the end of
the 1-yr extension and experienced a mean decrease in
LIC of 8.1 ± 7.4 mg Fe⁄g dw; ﬁve (7.2%) patients pro-
gressed to ‡2500 ng⁄mL by the end of the 1-yr extension
with a mean increase in LIC of 6.5 ± 5.3 mg Fe⁄g dw.
Of 142 patients with baseline serum ferritin levels
‡2500 ng⁄mL, 90 (63.4%) patients maintained this level
by the end of the 1-yr extension and experienced a mean
reduction in LIC of 2.4 ± 9.8 mg Fe⁄g dw; 52 (36.6%)
patients progressed to serum ferritin levels
<2500 ng⁄mL by the end of the 1-yr extension with a
mean reduction in LIC of 13.4 ± 5.6 mg Fe⁄g dw.
Overall mean LIC decreased from 19.6 ± 9.2 mg Fe⁄g
dw at core baseline to 13.4 ± 11.9 mg Fe⁄g dw by the
end of the 1-yr extension (Fig. 1A), and this represents a
signiﬁcant mean decrease of 6.6 ± 9.4 mg Fe⁄gd w
(P < 0.001; relative change )32.4%). At core baseline,
33.9% of patients (79⁄233) had LIC <15 mg Fe⁄g dw,
which increased to 55.8% (130⁄233) at extension baseline
and 67.8% (143⁄211) at the end of year 1 of the exten-
sion. In these patients where the serum ferritin level
reached <2500 ng⁄mL by the end of the 1-yr extension,
mean LIC decreased by 10.5 ± 7.2 mg Fe⁄g dw; in those
with serum ferritin level ‡2500 ng⁄mL at the end of the
1-yr extension, mean LIC decreased by 1.9 ± 9.8 mg
Fe⁄g dw. Serum ferritin levels decreased steadily in the
entire population during the core and extension studies,
with a median reduction of 929 ng⁄mL (range )7978 to
)3983, P < 0.0001; relative change )30.2%) by the end
of year 1 of the extension. Decreases in serum ferritin
levels were reﬂective of dose escalation in the overall
population. Overall, 32.6% (76⁄233), 40.3% (94⁄233)
and 54.2% (122⁄225) of patients had serum ferritin levels
of <2500 ng⁄mL at core baseline, extension baseline and
end of year 1 of the extension, respectively.
Efﬁcacy in paediatric and adult patients. The reduction
in LIC over the initial 2-yr treatment period was
5.7 ± 9.1 mg Fe⁄g dw in paediatric patients (19.1 ± 9.0
to 13.8 ± 11.5) and 8.5 ± 9.9 mg Fe⁄g dw (20.7 ± 9.8–
12.6 ± 12.8) in adults (P<0.0001 for both, Fig. 1A).
Decreases in serum ferritin levels over the same period
were reﬂective of dose escalation in both paediatric and
adult patients (Fig. 1B,C). The overall reduction in
serum ferritin levels from core baseline to the end of year
1 of the extension was 853 ng⁄mL (3326–2474) in paedi-
atric patients and 1254 ng⁄mL (3396–1776) in adult
patients (P < 0.0001 for both).
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Figure 1 (A) Mean change in liver iron concen-
tration ± SD from core baseline to end of year
1 of the extension in paediatric, adult and all
patients. Mean actual deferasirox ± SD dose
and median serum ferritin levels ± 25th⁄75th
percentiles from core baseline to end of year 1
of the extension in (B) paediatric and (C) adult
patients. Note: iron intake values shown in (A)
are from the core baseline until the end of the
1-yr extension.
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received an average actual dose of ‡30 mg⁄kg⁄d in the
1-yr extension, LIC decreased signiﬁcantly by
3.9 ± 6.6 mg Fe⁄gd w( P < 0.0001). In patients who
received an actual dose of <30 mg⁄kg⁄d mean LIC
decreased by 2.5 ± 5.5 mg Fe⁄gd w( P < 0.0001)
(Fig. 2A). A comparison of relative percentage change in
LIC in the 1-yr extension between the ‡30 mg⁄kg⁄d and
<30 mg⁄kg⁄d groups revealed that this change was not
signiﬁcantly different between both cohorts (P = 0.932).
In patients who received an average actual dose of
‡30 mg⁄kg⁄d, the median decrease in serum ferritin lev-
els during year 1 of the extension was signiﬁcant at
937 ng⁄mL (P < 0.0001); in patients who received an
average actual dose of <30 mg⁄kg⁄d, there was a signiﬁ-
cant median decrease of 493 ng⁄mL (P < 0.0001)
(Fig. 2B). A comparison of relative percentage change in
serum ferritin levels in the 1-yr extension between the
‡30 mg⁄kg⁄d and <30 mg⁄kg⁄d groups also revealed
that this change was not signiﬁcantly different between
these two groups (P = 0.832).
Efﬁcacy during year 2 of the extension. In total, 167
patients entered year 2 of the extension study. The median
duration of exposure in year 2 of the extension was 276 d,
and a total of 51 patients had serum ferritin assessments at
36 months. During this period, the number of patients
remaining in the study declined; patients received deferasi-
rox for varying durations that were related to the commer-
cial availability of deferasirox in each participating
country. Mean LIC at the start of year 2 of the extension
was 15.6 ± 11.9 mg Fe⁄g dw, with a mean decrease of
3.0 ± 5.7 mg Fe⁄gd w( P < 0.0001) from this point to
the end of the study. Median serum ferritin decreased by
213 ng⁄mL during the same period (last observation car-
ried forward at the median exposure), from 2851 ng⁄mL
at the start of year 2 of the extension.
Safety and tolerability
Overall, 216 patients (92.7%) completed the extension
study; overall median exposure to study drug was
88.1 wk (1.7 yr) during the extension. Of the 17 discon-
tinuations, 10 and seven occurred in years 1 and 2 of the
extension, respectively. Reasons for discontinuation were
as follows: loss to follow-up (n=8, 3.4%), AEs (n=3,
1.3%), death (n=3, 1.3%), protocol violation (n=2,
0.9%) and consent withdrawal (n=1, 0.4%). Of the
three deaths reported during the extension study, one
was a paediatric patient (as a result of respiratory fail-
ure) and two were adults (as a result of cerebral and sub-
arachnoid haemorrhage); none were considered to be
related to study drug. Of the three AEs that led to dis-
continuation, only one (abdominal discomfort in an
adult) was considered by the investigators to be drug
related and the other two AEs were cardiac failure and
hypotension (in a paediatric and adult patient, respec-
tively). This single incidence of cardiac failure was
related to progression of the underlying disease.
During the core and extension studies, AEs regardless
of relationship to study drug were reported by 201
(87.0%) patients. AEs that were considered by the inves-
tigators to be drug related were noted in 126 patients
(54.5%), and most (>95%) were mild to moderate in
nature. The most commonly reported drug-related AEs
are summarised in Table 2. The overall pattern and
frequency of AEs were generally comparable between the
paediatric and adult populations; however, of the most
commonly reported AEs, nausea and increased serum
creatinine levels were observed more frequently in adult
patients, while vomiting and increased alanine amino-
transferase (ALT) were noted more frequently in paediat-
ric patients. Fifty-ﬁve patients (23.8%) reported drug-
related AEs in the extension study, compared with 105
patients (44.3%) solely in the core study (9).
B A
Figure 2 (A) Mean absolute change in liver iron
concentration ± SD and (B) median absolute
change in serum ferritin levels ± 25th and 75th
percentiles from extension baseline to end of
year 1 of the extension in patients who
received mean actual deferasirox doses of <30
or ‡30 mg⁄kg⁄d.
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The most common were upper abdominal pain (n=3,
1.3%), upper limb fractures (n=3, 1.3%), vomiting
(n=3, 1.3%) and cholecystitis (n=3, 1.3%). Three
serious AEs were considered to be related to the study
drug: severe peptic ulcer perforation (n=1), moderate
increased serum creatinine levels (n=1) and moderate
cholestatic jaundice (n=1).
Renal and hepatic function. Eight patients (3.5%) had
two consecutive serum creatinine level increases >33%
above core baseline and greater than upper limit of nor-
mal (ULN) in the core and extension studies; six of these
were paediatric patients and two were adult patients. All
eight patients continued to receive deferasirox during the
core and extension studies. Creatinine levels had returned
to within the normal range at the last assessment per-
formed in six (four paediatric and two adult) of these
patients. One adult patient of these eight had multiple
serious AEs including cholecystitis, elevated serum creati-
nine levels, congestive cardiac failure and arrhythmia,
although all these events resolved. Overall mean serum
creatinine levels remained stable over the core and exten-
sion studies, irrespective of average actual deferasirox
dose received (Fig. 3A).
Eight patients (3.5%), six paediatric and two adult,
had two consecutive increases in ALT > 10 · ULN, and
baseline levels were already elevated in ﬁve patients.
ALT levels at the last assessment were below baseline in
ﬁve of the eight patients. Two of the remaining three
patients had normal levels at baseline; therefore, only
one patient with elevated baseline ALT still had elevated
levels at the last assessment and this patient continued to
receive deferasirox. One patient of these eight discontin-
ued with deferasirox.
The mean level of ALT at core baseline was
62.7 ± 46.6 U⁄L( n=230) and had decreased to
41.7 ± 40.9 U⁄L( n=181) at the end of the extension
study, representing an overall signiﬁcant decrease of
24.8 ± 48.2 U⁄L( P < 0.0001; relative change )5.8 ±
137.1%, Fig. 3B). Mean aspartate aminotransferase
(AST) levels decreased signiﬁcantly from 50.4 ± 33.9
U⁄L( n=230) to 41.0 ± 30.3 U⁄L( n=181) over the
same treatment period, and overall mean decrease was
11.7 ± 27.7 U⁄L( P < 0.0001; relative change )11.5 ±
60.3%).
Cardiac function. During deferasirox treatment, there
was a statistically signiﬁcant increase in mean LVEF
from 65.2 ± 6.8% at core baseline to 68.2 ± 7.8%
(n=171) at the end of the extension study (mean
increase 2.3 ± 8.6% and P = 0.0007).
Paediatric growth and development. Overall, 162 paedi-
atric patients (aged 2–<16) entered the extension study.
As previously reported, at core baseline males and
females in all age groups were shorter than those in the
Center for Disease Control reference population (9).
Steady increases in height were noted for paediatric
patients aged 2–<16 over the treatment period. Absolute
change for h-SDS indicated that the growth of paediatric
patients predominantly followed the normal trends
derived from US clinical growth charts (Fig. 4A). Sexual
development in patients aged ‡12–<16 yr, as evaluated
by Tanner stage assessments, also progressed normally
during the course of deferasirox treatment and was com-
parable with a US reference population (14). The pro-
portion of patients at Tanner stage 5 for female breast
development increased from 6.9% at core baseline to
41.4% at the end of the entire extension (Fig. 4B). At
core baseline, 6.9% of male patients were at Tanner
stage 5 for testicular volume, which increased to 27.6%
by the end of the entire extension (Fig. 4C).
Discussion
ESCALATOR was the ﬁrst study to evaluate whether a
ﬁxed starting dose of deferasirox 20 mg⁄kg⁄d, followed
by dose titration based on iron burden and transfusional
iron intake, could provide effective iron chelation in
heavily iron-overloaded patients with b-thalassaemia
Table 2 Most common (>3%) drug-related adverse events (AEs)
AE Overall
(n=231)
Core
1
(n=237)
Extension
(n=231)
Paediatric
patients (n=162)
Adult patients
(n=69)
<30 mg⁄kg
(n=204)
‡30 mg⁄kg
(n=27)
Median deferasirox
exposure, weeks
140.1 52.3 88.1 143.9 122.3 139.4 155.0
Nausea 16 (6.9) 17 (7.2) 4 (1.7) 6 (3.7) 10 (14.4) 11 (5.4) 5 (18.5)
Vomiting 28 (12.1) 21 (8.9) 14 (6.1) 21 (13.0) 7 (10.1) 24 (11.8) 4 (14.8)
Increased ALT
2 23 (10.0) 13 (5.5) 16 (6.9) 18 (11.1) 5 (7.2) 20 (9.8) 3 (11.1)
Increased serum
creatinine
2
23 (10.0) 9 (3.8) 14 (6.1) 8 (4.9) 15 (21.7) 20 (9.8) 3 (11.1)
Rash 20 (8.7) 19 (8.0) 2 (0.9) 13 (8.0) 7 (10.1) 16 (7.8) 4 (14.8)
ALT, alanine aminotransferase.
1Ref. 9.
2Reported as an AE by the investigator.
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patients’ overall LIC and serum ferritin levels were sig-
niﬁcantly reduced from baseline. In addition, based on
prospectively deﬁned criteria, a statistically signiﬁcant
proportion of patients achieved treatment success
(67.4%; P < 0.0001) vs. 57% at the end of the core
study. It should be noted that time to ﬁrst dose increase
in the core study was later than required for effective
iron chelation. Dose increases to ‡30 mg⁄kg⁄d were gen-
erally required in this population of heavily transfused,
iron-overloaded patients, and ﬁnal deferasirox dose at
the end of the extension study was ‡30 mg⁄kg⁄d in 66%
of patients. These ﬁndings are consistent with earlier def-
erasirox studies, which found that £20 mg⁄kg⁄d is not
sufﬁcient to signiﬁcantly reduce iron burden in heavily
iron-overloaded patients with thalassaemia (6, 15, 16).
The recommended initial daily starting dose of deferasi-
rox is 20 mg⁄kg⁄d for most patients. For patients with a
higher transfusional iron intake (e.g > 14 mL⁄kg⁄month
packed red blood cells for adults), a starting dose of
30 mg⁄kg⁄d is recommended. For patients experiencing
poor control of iron overload at doses up to
30 mg⁄kg⁄d, dosing up to a maximum of 40 mg⁄kg⁄d
may be required (17). Compared with patients who
received an average actual deferasirox dose of
<30 mg⁄kg⁄d, those who received ‡30 mg⁄kg⁄d during
the extension had higher LIC and serum ferritin levels at
extension baseline and subsequently achieved greater
decreases in these iron parameters at the end of year 1 of
the extension despite a higher transfusional iron intake
(0.40 ± 0.10 mg⁄kg⁄d vs. 0.32 ± 0.09 mg⁄kg⁄d). This
observation highlights that timely dose increases above
30 mg⁄kg⁄d are necessary for effective reduction of iron
in patients with heavy iron burden and high iron intake.
Thus, patients with heavy iron overload may require
rapid dose titration to meet therapeutic goals of iron
reduction. The results presented here support the
concept of higher initial starting doses followed by dose
titrations.
Substantial decreases in serum ferritin levels and LIC
beyond those in the core study were observed after year
1 of the extension study in both paediatric and adult
A
B
Figure 3 (A) Serum creatinine levels stratiﬁed
by dose category. Note: The boxes represent
the 25th and 75th percentiles, while the whis-
kers correspond to the 10th and 90th percen-
tiles. The medians are connected. Outliers
‡95% are indicated as individual points. (B) ALT
levels at core baseline and at the end of exten-
sion study.
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adult population despite both populations having compa-
rable baseline LIC and serum ferritin, and a similar
pattern of response was observed at the end of the core
study (9). A number of possible explanations can be con-
sidered for the difference between the populations, such
as the higher transfusional iron intake (0.36 vs.
0.28 mg⁄kg⁄d), the longer median time to ﬁrst dose
increase (40 vs. 26 wk) and the lower mean actual dose
received by paediatric patients than by adults. In addi-
tion to the clinical practice of more frequent transfusion
in paediatric patients, previous pharmacokinetic studies
have also shown that systemic exposure to deferasirox is
lower in children (13) than in adults (15, 16). The slower
rate of dose titration in paediatric patients may be
related to investigators using a more conservative
approach to dose escalation in this population in the
light of limited safety data at the time of study conduct.
However, robust safety data have emerged on the use of
deferasirox (6, 18–20), including in paediatric patients
(21, 22). Taken together, these results highlight the
importance of timely dose increases and demonstrate
that deferasirox increases to ‡30 mg⁄kg⁄d are necessary
in heavily iron-overloaded paediatric patients as well as
in adults.
At core baseline, mean LIC and median serum ferritin
levels were above the thresholds associated with signiﬁ-
cant negative outcomes (>15 mg Fe⁄g dw and
>2500 ng⁄mL, respectively) (23, 24), which meant that
these patients were at high risk for cardiac complications
and death despite the fact that all were previously treated
with DFO and⁄or deferiprone as a monotherapy or com-
bination therapy. This observation suggests that these
patients were not adequately chelated before entering the
study, perhaps because of issues with compliance, drug
response or toxicity. It is encouraging to note that during
2 yr of deferasirox treatment, an increasing proportion
of patients achieved LIC <15 mg Fe⁄g dw (33.9% to
67.8%) and serum ferritin levels <2500 ng⁄mL (32.6%
to 54.2%). This demonstrates that with appropriate dos-
ing over the long term, these higher risk patients can be
brought into iron control. Other longer-term studies have
shown that with continued treatment, an increasing per-
centage of patients can achieve iron control within the
target range of serum ferritin <2500 ng⁄mL and⁄or LIC
<7 mg Fe⁄g dw (21).
Deferasirox was generally well tolerated with a clini-
cally manageable safety proﬁle and a low discontinuation
rate during the entire treatment period of this study. The
overall safety proﬁle was consistent with previous obser-
vations in patients with b-thalassaemia (6, 15, 16) and
was generally similar between adult and paediatric
patients. The frequency of drug-related AEs decreased in
the extension compared with the core study, despite dose
A
B
C
Figure 4 (A) Median absolute change in h-SDS ± 25th and 75th per-
centiles for male and female paediatric patients during the core and
extension study. Whiskers represent maximum and minimum values.
(B) Tanner stage assessments of breast development in females and
(C) testes volume in males.
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gesting that AEs generally occur early in treatment and
are mostly transient. Given the low rate of discontinua-
tion observed in this study, this reduction is unlikely to
be caused by patients experiencing AEs who discontin-
ued from the trial. Furthermore, there were no progres-
sive increases in serum creatinine or liver transaminase
levels over the study period. Indeed, signiﬁcant decreases
in the levels of ALT and AST were observed over the
course of the study, indicating improved liver function
possibly as a result of hepatic iron chelation. Improved
liver function with effective iron chelation has been seen
in a number of other deferasirox trials across a variety
of underlying anaemia (25–27). Improvement in LVEF
within the normal range was observed after 2 yr of defer-
asirox treatment, suggesting a positive effect of deferasi-
rox on cardiac function, although patients’ myocardial
iron status was not evaluated in this study. Data from a
separate study showed stabilization of LVEF in patients
with mild-to-moderate and severe cardiac siderosis after
2 yr of deferasirox treatment (28).
To assist with treatment compliance, which is essential
for effective control of iron overload (29, 30), it is impor-
tant for physicians to discuss potential AEs with their
patients before initiating deferasirox therapy and to reas-
sure patients that if these events do occur then they can
be readily managed. Furthermore, the patient should be
aware that these events are usually mild and will most
often resolve even if they continue to take deferasirox.
Of note, increased deferasirox doses in the paediatric
population did not result in any signiﬁcant increases in
AEs. Furthermore, physical development progressed nor-
mally during deferasirox treatment. Sexual development
also progressed normally according to Tanner stage
assessment of patients aged ‡12–<16 yr when compared
to a US population, although published data for Middle
Eastern children are lacking. This highlights that defer-
asirox can effectively control body iron burden without
any growth-related safety concerns, which is important
given that growth retardation and hypogonadism
because of iron overload and DFO-induced toxicity are
signiﬁcant clinical problems in paediatric patients with
b-thalassaemia (2, 3). It should be noted however that
h-SDS are somewhat limited because of comparisons
with a non-thalassaemia North American control popu-
lation. These data from a single study and over longer
time horizons are consistent with previous ﬁndings
from pooled studies highlighting that deferasirox
>30 mg⁄kg⁄d has a clinically manageable safety proﬁle
similar to that seen with doses of <30 mg⁄kg⁄d (31).
In conclusion, following treatment with deferasirox,
LIC and serum ferritin levels were signiﬁcantly decreased
by 32.4% and 30.2%, respectively, during the initial 2 yr
of treatment in these heavily iron-overloaded patients
with b-thalassaemia. Doses of ‡30 mg⁄kg⁄d were
required in most patients because of high transfusional
iron intake and heavy iron burden at baseline, highlight-
ing the importance of administering sufﬁcient deferasirox
to achieve the clinical goal of net iron reduction. With
longer exposure and at doses ‡30 mg⁄kg⁄d, deferasirox
had a clinically manageable safety proﬁle and was gener-
ally well tolerated.
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